Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen X Chen

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
The Oncologist|March 27, 2014
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment responseXiaochun Liu, Patricia Lorusso, Monica Mita, et al.
Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancerAung Naing, Razelle Kurzrock, Angelika Burger, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
British Journal of Haematology|April 27, 2011
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialGeorge Somlo, Ashkan Lashkari, William Bellamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyLeonard B Saltz, Heinz-Josef Lenz, Hedy L Kindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
The Oncologist|March 27, 2014
Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment responseXiaochun Liu, Patricia Lorusso, Monica Mita, et al.
Breast Cancer Research and Treatment|April 23, 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancerCynthia X Ma, Vera J Suman, Matthew Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancerAung Naing, Razelle Kurzrock, Angelika Burger, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
British Journal of Haematology|April 27, 2011
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialGeorge Somlo, Ashkan Lashkari, William Bellamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyLeonard B Saltz, Heinz-Josef Lenz, Hedy L Kindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
Journal for Immunotherapy of Cancer|October 21, 2025
Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of <i>D</i>ual <i>A</i>nti-CTLA-4 and Anti-PD-1 blockade in <i>R</i>are <i>T</i>umors (DART) SWOG S1609 (Cohort 38)Sandip P Patel, Megan Othus, Young K Chae, et al.
Cancer Investigation|January 12, 2005
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialRamesh K Ramanathan, Jimmy J Hwang, William C Zamboni, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Pageof 9